Biotech · Public company · Cambridge, MA, US
Seres Therapeutics, Inc.
Ticker MCRB · SEC CIK 0001609809
Track this companyFree. Adds Seres Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline8
- SER-109Phase 3 · Clostridioides Difficile InfectionClinicalTrials.gov · fetched Nov 12, 2026
- SER-109Phase 3 · Clostridium Difficile InfectionClinicalTrials.gov · fetched Nov 12, 2026
- SER-287Phase 2 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- Vancomycin Pre-TreatmentPhase 2 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- SER-155Phase 1 · Allogeneic Hematopoietic Stem Cell TransplantationClinicalTrials.gov · fetched Nov 12, 2026
- SER-262Phase 1 · Clostridium Difficile InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Vancomycin Pre-TreatPhase 1 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- Vancomycin Pre-TreatmentPhase 1 · Allogeneic Hematopoietic Stem Cell TransplantationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCTPHASE1 · COMPLETED · started Nov 24, 2021ClinicalTrials.gov NCT04995653 · fetched Nov 12, 2026
- Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome InterventionPHASE1 · COMPLETED · started Jan 28, 2019ClinicalTrials.gov NCT03817125 · fetched Nov 12, 2026
- A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative ColitisPHASE2 · TERMINATED · started Dec 19, 2018ClinicalTrials.gov NCT03759041 · fetched Nov 12, 2026
- ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile InfectionPHASE3 · COMPLETED · started Oct 23, 2017ClinicalTrials.gov NCT03183141 · fetched Nov 12, 2026
- ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile InfectionPHASE3 · COMPLETED · started Jul 10, 2017ClinicalTrials.gov NCT03183128 · fetched Nov 12, 2026
- SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent RecurrencePHASE1 · COMPLETED · started Aug 1, 2016ClinicalTrials.gov NCT02830542 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative ColitisPHASE1 · COMPLETED · started Jan 13, 2016ClinicalTrials.gov NCT02618187 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 1, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026